5-叔丁基-2-对甲苯基-2H-吡唑-3-胺 | 285984-25-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 5-叔丁基-2-对甲苯基-2H-吡唑-3-胺
• 中文别名: 5-叔丁基2-对甲苯基-2H-吡唑-3-胺；5-氨基-3-叔丁基-1-(4-甲苯基)吡唑
• 英文名称: 3-tert-butyl-1-p-tolyl-1H-pyrazol-5-amine
• 英文别名: 5-tert-butyl-2-p-tolyl-2H-pyrazol-3-ylamine；3-amino-5-tert-butyl-2-p-tolyl-2H-pyrazole；5-tert-butyl-2-p-methylphenyl-3-aminopyrazole；3-tert-butyl-1-(4-methylphenyl)-1H-pyrazol-5-amine；5-amino-3-(tert-butyl)-1-(p-tolyl)-1H-pyrazole；5-tert-butyl-2-(4-methylphenyl)pyrazol-3-amine
• CAS: 285984-25-0
• 化学式: C₁₄H₁₉N₃
• mdl: MFCD04115090
• 分子量: 229.325
• InChiKey: ITHNHEWXIBNEDG-UHFFFAOYSA-N

物化性质

• 沸点：
  368.3±37.0 °C(Predicted)
• 密度：
  1.06±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.357
• 拓扑面积：
  43.8
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933199090
• 危险标志：
  GHS07
• 危险性描述：
  H302
• 危险性防范说明：
  P280,P305+P351+P338
• 储存条件：
  2-8°C

反应信息

• 作为反应物：
  描述：

  5-叔丁基-2-对甲苯基-2H-吡唑-3-胺 在 碳酸氢钠 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 甲苯 为溶剂， 反应 0.25h， 生成 1-[2-(4-甲基苯基)-5-叔丁基吡唑-3-基]-3-[4-(2-吗啉-4-基乙氧基)萘-1-基]脲
  参考文献：
  名称：

  Pyrazole Urea-Based Inhibitors of p38 MAP Kinase:  From Lead Compound to Clinical Candidate

  摘要：

  We report on a series of N-pyrazole, N'-aryl ureas and their mode of binding to p38 mitogen activated protein kinase. Importantly, a key binding domain that is distinct from the adenosine 5'-triphoshate (ATP) binding site is exposed when the conserved activation loop, consisting in part of Asp168-Phe169-Gly170, adopts a conformation permitting lipophilic and hydrogen bonding interactions between this class of inhibitors and the protein. We describe the correlation of the structure-activity relationships and crystallographic structures of these inhibitors with p38. In addition, we incorporated another binding pharmacophore that forms a hydrogen bond at the ATP binding site. This modification affords significant improvements in binding, cellular, and in vivo potencies resulting in the selection of 45 (BIRB 796) as a clinical candidate for the treatment of inflammatory diseases.

  DOI：

  10.1021/jm020057r
• 作为产物：
  描述：

  4-甲基苯肼盐酸盐 以82 %的产率得到5-叔丁基-2-对甲苯基-2H-吡唑-3-胺
  参考文献：
  名称：

  DIHYDRO[1,8]NAPHTHYRIDIN-7-ONE AND PYRIDO[3,2-B][1,4]OXAZIN-3-ONE FOR USE IN TREATING CANCER, AND METASTASES IN PARTICULAR.

  摘要：

  本发明提供用于治疗、改善、延缓、治愈和/或预防癌症的化合物。特别地，本发明涉及通式(I)的化合物或药学上可接受的其盐，及其用于治疗癌症和/或用于减少或预防癌症患者转移的出现。本发明还涉及通式(II)的新化合物或药学上可接受的其盐，及其作为药物的用途，特别是用于治疗癌症和/或用于减少或预防癌症患者转移的出现。

  公开号：

  EP4289427A1
• 作为试剂：
  描述：

  5-叔丁基-2-对甲苯基-2H-吡唑-3-胺 、 1-amino-4-(2-morpholin-4-yl-ethoxy)naphthalene dihydrochloride 在 5-叔丁基-2-对甲苯基-2H-吡唑-3-胺 作用下， 以22的产率得到1-[2-(4-甲基苯基)-5-叔丁基吡唑-3-基]-3-[4-(2-吗啉-4-基乙氧基)萘-1-基]脲
  参考文献：
  名称：

  J. Med. Chem. 2002, 45, 2994-3008

  摘要：

  DOI：

文献信息

• [EN] BICYCLIC HETEROARYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS<br/>[FR] COMPOSÉS D'HÉTÉROARYLE URÉE, THIOURÉE,GUANIDINE ET CYANOGUANIDINE EN TANT QU'INHIBITEURS DE LA KINASE TRKA
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2014078408A1

  公开（公告）日：2014-05-22

  Compounds of Formula I or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.

  式I化合物或其立体异构体、互变异构体或药学上可接受的盐、溶剂合物或前药，其中环A、环C和X如本文所定义，是TrkA激酶的抑制剂，并且在治疗可以用TrkA激酶抑制剂治疗的疾病中具有用处，如疼痛、癌症、炎症/炎症性疾病、神经退行性疾病、某些传染病、干燥综合征、子宫内膜异位症、糖尿病周围神经病变、前列腺炎和盆腔疼痛综合征。
• [EN] MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS, METHODS OF MAKING, AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS DE PROTÉINES KINASES ACTIVÉS PAR MITOGÈNE, PROCÉDÉS DE PRODUCTION ET PROCÉDÉS D'UTILISATION ASSOCIÉS
  申请人：UNIV WASHINGTON

  公开号：WO2019232275A1

  公开（公告）日：2019-12-05

  Compounds that inhibit mitogen-activated protein kinases (MAPKs) are disclosed. Some inhibitor compounds specifically target a single MAPK such as MAPK13, while others target multiple MAPKs such as MAPK13 and MAPK12. The compounds can be used therapeutically for a variety of diseases, including cancer and respiratory diseases. Methods of synthesis of the compounds are also disclosed.

  抑制丝裂原活化蛋白激酶（MAPKs）的化合物已被披露。一些抑制剂化合物特异性地靶向单个MAPK，如MAPK13，而其他一些则靶向多个MAPK，如MAPK13和MAPK12。这些化合物可用于治疗各种疾病，包括癌症和呼吸道疾病。该化合物的合成方法也已被披露。
• P38 inhibitors and methods of use thereof
  申请人：——

  公开号：US20040192653A1

  公开（公告）日：2004-09-30

  This invention relates to inhibitors of p38, and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing the inhibitors and pharmaceutical compositions in the treatment and prevention of various disorders mediated by p38.

  这项发明涉及p38的抑制剂，以及生产这些抑制剂的方法。该发明还提供了包括该发明的抑制剂的药物组合物，以及利用这些抑制剂和药物组合物在治疗和预防由p38介导的各种疾病中的方法。
• INHIBITORS OF HEMOPOIETIC CELL KINASE (P59-HCK) AND THEIR USE IN THE TREATMENT OF INFLUENZA INFECTION
  申请人：Charron Catherine Elisabeth

  公开号：US20120244120A1

  公开（公告）日：2012-09-27

  The present invention relates inter alia to the treatment or prevention of influenza virus infection (including subtypes influenza A virus, influenza B virus, avian strain H5N1, A/H1N1, H3N2 and/or pandemic influenza) using compounds which inhibit the activity of p59-HCK and to a method of screening for a candidate drug substance intended to prevent or treat influenza virus infection in a subject, said method comprising identifying a test substance capable of inhibiting p59-HCK activity.

  本发明涉及治疗或预防流感病毒感染（包括亚型流感A病毒、流感B病毒、禽流感H5N1、A/H1N1、H3N2和/或大流行性流感）的化合物，这些化合物抑制p59-HCK的活性，并涉及一种筛选候选药物物质的方法，该方法旨在预防或治疗受试者的流感病毒感染，所述方法包括识别能够抑制p59-HCK活性的试验物质。
• Synthesis and Biological Evaluation of Chromenylurea and Chromanylurea Derivatives as Anti-TNF-α agents that Target the p38 MAPK Pathway
  作者：Xingzhou Li、Xinming Zhou、Jing Zhang、Lili Wang、Long Long、Zhibing Zheng、Song Li、Wu Zhong

  DOI：10.3390/molecules19022004

  日期：——

  A series of 1-aryl-3-(2H-chromen-5-yl)urea and 1-aryl-3-(chroman-5-yl)urea derivatives were designed, synthesized and evaluated for their inhibitory activities towards TNF-α production in lipopolysaccharide-stimulated THP-1 cells. The most active compound, 40g, inhibited TNF-α release with an IC50 value of 0.033 μM, which is equipotent to that of BIRB796 (IC50 = 0.032 μM).

  设计、合成并评估了一系列1-芳基-3-(2H-色烯-5-基)脲和1-芳基-3-(色满-5-基)脲衍生物对脂多糖刺激的THP-1细胞中TNF-α产生抑制活性。活性最高的化合物40g能以0.033 μM的IC50值抑制TNF-α的释放，与BIRB796的效力相当（IC50 = 0.032 μM）。